Acurx: A Single Trial, a Microbiome Edge, and a Runway to the Unknown

A Pivotal Fork

Acurx Pharmaceuticals (ACXP) is a micro-cap antibiotic developer that has been in a brutal drawdown – the stock has lost 99% since its 2021 peak and is down another 44% over the last three months. But the company's August 14 earnings call unveiled a concrete regulatory catalyst that could change the trajectory of its lead asset, ibezapolstat. The FDA, in a July meeting, signaled openness to a single Phase III trial – the IBZ-ASPIRE study – for acute C. difficile infection (CDI), with the smaller PATHFINDER study in recurrent disease serving as supportive evidence. As President and CEO David Luci put it, “the FDA stated that it is open to further discussion on the totality of evidence from the ibezapolstat clinical development program at a pre-NDA meeting after completion of a single Phase III trial called IBZ-ASPIRE and any other clinical trials conducted prior to the pre-NDA meeting, which will include the PATHFINDER study, 20-patient open-label and recurrent CDI, particularly if the clinical efficacy results are robust.” — David Luci, President and CEO · 2026-08-14 This is not just an incremental step; it could halve the cost and time to approval for a company that has been seeking partnerships to fund its Phase III program.

The company is leaning on a differentiated mechanism: its DNA pol III C inhibitors are designed to be microbiome-sparing, which could reduce the risk of recurrence. New data from the University of Houston, presented in July, showed that ibezapolstat allows beneficial gut bacteria to repopulate and is superior to vancomycin and fidaxomicin in biofilm models. This ties directly to the regulatory narrative. Gut microbiome preservation is a key differentiator. In May, Medical Director Michael Silverman noted, “This new guidance refers back to a lineage of other FDA guidances going back to at least 2019, discussing the feasibility and the requirements for a single trial. What is very important is the new guidance, which is a final guidance, it's not a draft guidance, applies it specifically to C. difficile.” — Michael Silverman, Medical Director · 2026-05-12 That context is critical: the new final guidance explicitly opens the door to a single well-controlled trial with confirmatory evidence.

The company also announced a new scientific partnership with Leiden University Medical Center to further mechanistic research on DNA pol III C inhibitors, aiming to generate the first 3D structure of pol C from MRSA in complex with an Acurx inhibitor. This could expand the pipeline beyond CDI into other Gram-positive pathogens – a potential long-term value driver. Prior commentary from November 2025 reinforced the class-effect promise: “The data is compelling. I mean, to have a microbiome-sparing class effect, that means that as we get our second antibiotic in the pipeline into clinical trials, if our second program is effectively treating MRSA and anthrax and VRE, we'll be very confident that there are going to be very, very few or no reinfections because of the class effect of the microbiome-sparing mechanism of action.” — David Luci, President and CEO · 2025-11-12

The Cash Conundrum

But the elephant in the room is funding. The ASPIRE trial is not yet funded; the company is “prepared to commence its Phase III clinical trial program with the ASPIRE trial for the treatment of both CDI and reduction of recurrence pending appropriate funding from public or private sources or partnerships.” In the meantime, the PATHFINDER trial in recurrent CDI is fully funded and expected to begin enrollment in Q4 2026. Management stressed that PATHFINDER could also open a second approval pathway under the LPAD (Limited Population Pathway for Antibacterial and Antifungal Drugs). As Luci explained,

whether or not the ASPIRE trial is eventually funded, there's a second pathway to FDA approval under the LPAD pathway for recurrent C diff. So if we finish the 20 patients exploratory trial, open label, that we call PATHFINDER, we will meet with the FDA, and we have the possibility to be considered an LPAD pathway program, which will make – give us the ability to file for approval in recurrence C. difficile with just one Phase III trial, which may be somewhere in the neighborhood of half the price of one of the ASPIRE trials.

The company ended Q2 with $10.7 million in cash, up from $7.6 million at year-end, after raising $2.5 million in a registered direct offering and $0.8 million from its equity line. Yet that is not a lot of runway. Cash runway is 6.6 quarters, enough to complete PATHFINDER and fund operations into 2027, but not to run ASPIRE. The company is actively seeking partnerships and government funding, but as of now, the path to a pivotal trial remains contingent on external capital.

Meanwhile, the stock's recent 90-day return of -43.7% suggests the market is skeptical about the funding story, even as the regulatory news is arguably positive. The gap between the clinical promise and the balance sheet is stark. With a market cap of just $8 million, the company is trading at a very early stage of a high-risk, high-reward development story.

The confluence of a single-trial pathway, microbiome-sparing data, and a second approval route via LPAD gives Acurx multiple shots on goal. If PATHFINDER succeeds and the FDA agrees to the LPAD designation, the company could approach approval with a much smaller financial outlay. For a micro-cap with limited resources, that is the most interesting development in the news.

In the Q&A, management also confirmed that they have enough API and formulated product for both trials. As Executive Chairman Robert DeLuccia said, “we have plenty of API and also the formulated product is all ready to go to support the PATHFINDER trial, and we're poised to have enough API manufacturing with appropriate dating to start the ibezapolstat ASPIRE trial as well.” — Robert DeLuccia, Executive Chairman · 2026-08-14 And on the trial design, Medical Director Michael Silverman clarified that it is a non-inferiority trial versus vancomycin: “This is not a superiority trial. This is a noninferiority trial. So we don't have to show superiority over vancomycin for the clinical care acute treatment endpoint. We need to show noninferiority within standard bonds, which is a statistical concept but the lower limit would be confidence interval within 10%.” — Michael Silverman, Medical Director · 2026-08-14

Ultimately, the upcoming quarters will be defined by two variables: whether PATHFINDER enrollment goes as planned, and whether the company can secure the capital needed for ASPIRE. The FDA's openness to a single trial, combined with the microbiome story, makes this a company worth watching in the antibiotic space. ASPIRE trial is now the central catalyst, but PATHFINDER may be the sleeper that unlocks LPAD. The company's aggressive pursuit of multiple regulatory pathways is a pragmatic strategy for a small player in a difficult market.

As always in biotech, execution is everything. Acurx has survived on a shoestring budget, cutting costs and stretching its cash. The next 12 months will tell whether the FDA's encouraging words translate into a funded, initiated Phase III trial – or whether the company once again finds itself in a financing squeeze. The irony is that the science is arguably stronger than the stock price suggests. But for now, investors are betting on cash, not just on molecules.